IFRX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

IF

Mkt Cap

$194.5M

Volume

1.53M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementInflaRx N.V. (Nasdaq: IFRX) announced it received a notice from Nasdaq on March 11, 2026, indicating that its ordinary shares have closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until September 7, 2026, to regain compliance, with a potential additional 180-day grace period if it transfers to the Nasdaq Capital Market. The notice has no immediate effect on trading.GlobeNewswire Inc. · Mar 13, 2026

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumInflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. The company will focus on its oral inhibitor INF904 and consider cost-saving measures.GlobeNewswire Inc. · May 28, 2025

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsInflaRx N.V. announced the pricing of its public offering of 8,250,000 ordinary shares and 6,750,000 pre-funded warrants at $2.00 per share. The company intends to use the net proceeds to fund the clinical development of its pipeline candidates and for general corporate purposes.GlobeNewswire Inc. · Feb 14, 2025

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeInflaRx's anti-C5a antibody vilobelimab has received a positive opinion from the CHMP of the EMA for the treatment of SARS-CoV-2-induced ARDS. The positive opinion is based on the results of the PANAMO trial, which showed improved survival with vilobelimab treatment.GlobeNewswire Inc. · Nov 15, 2024

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS).GlobeNewswire Inc. · Jun 24, 2024

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsJENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.GlobeNewswire Inc. · May 21, 2024

InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateJENA, Germany, May 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced financial results for the three months ended March 31, 2024, and provided an operating update.GlobeNewswire Inc. · May 8, 2024

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventJENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.GlobeNewswire Inc. · Apr 24, 2024

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue EstimatesInflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · Mar 21, 2024

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.GlobeNewswire Inc. · Mar 19, 2024

IF

IFRXInflaRx N.V. Common Stock

IFRX

Pay with—

Available Balance0.00

Your PositionYou don't own any IFRX yet.

Related Tickers

Earnings